Idéal Investisseur
Français English
CAC 40 : Market open
8 291,04 pts
-0.10%


Last updated : 07/05/2026 - 12h37
🏠 Home   ➤    Stock news

Argenx: Karen Massey Appointed CEO, Tim Van Hauwermeiren Named Chairman

Argenx has announced the appointment of Karen Massey as CEO by the board of directors, following shareholder approval of her addition to the board.


Argenx: Karen Massey Appointed CEO, Tim Van Hauwermeiren Named Chairman

CEO Succession

Karen Massey, who joined Argenx in March 2023 as Chief Operating Officer, has been promoted to CEO. She succeeds Tim Van Hauwermeiren, who founded the company and has been the CEO since 2008. Her appointment follows shareholder approval of her addition to the board of directors as an executive member. Tim Van Hauwermeiren has been appointed chairman of the board of directors, effective immediately, after transitioning to a non-executive director.

Quorum and Voting

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

The annual general meeting saw 90.9% of the share capital represented. All items on the agenda received the required majority of favorable votes, including the appointments of Karen Massey as CEO and Tim Van Hauwermeiren as chairman.



Sector Santé · Biotechnologies · Pharmacie Biotechnologie


Assurance vie

Context

Period
  • Period: 1T2026
Key reported figures
  • Revenue: 1.3MD€
  • Net income: 366M€
Guidance from the release
  • argenx continue de livrer un impact significatif pour les patients.
  • Argentx affiche une croissance de 63% par rapport à l'année précédente.
Risks mentioned
  • Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
  • L'impact des lois et règlements gouvernementaux pourrait affecter les activités.
Opportunities identified
  • VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
  • Lancement d'une étude pour le candidat pipeline empasiprubart.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit